APA

Miltiades P., Lamprianidou E., Vassilakopoulos T. P., Papageorgiou S. G., Galanopoulos A. G., Vakalopoulou S., Garypidou V., Papaioannou M., Hadjiharissi E., Pappa V., Papadaki H. A., Spanoudakis E., Tsatalas K. & Kotsianidis I. (20140303). Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. : Blood cancer journal.

Chicago

Miltiades P, Lamprianidou E, Vassilakopoulos T P, Papageorgiou S G, Galanopoulos A G, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki H A, Spanoudakis E, Tsatalas K and Kotsianidis I. 20140303. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. : Blood cancer journal.

Harvard

Miltiades P., Lamprianidou E., Vassilakopoulos T. P., Papageorgiou S. G., Galanopoulos A. G., Vakalopoulou S., Garypidou V., Papaioannou M., Hadjiharissi E., Pappa V., Papadaki H. A., Spanoudakis E., Tsatalas K. and Kotsianidis I. (20140303). Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. : Blood cancer journal.

MLA

Miltiades P, Lamprianidou E, Vassilakopoulos T P, Papageorgiou S G, Galanopoulos A G, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki H A, Spanoudakis E, Tsatalas K and Kotsianidis I. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. : Blood cancer journal. 20140303.